GSK Unveils New Blood Cancer Data at ASH 2025 Meeting

GSK plc will showcase new data from its haematology portfolio at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, scheduled from 6–9 December, underlining its commitment to improving outcomes for patients with difficult-to-treat blood cancers. Updated findings from the DREAMM programme for belantamab mafodotin highlight its potential to prolong remission in relapsed or refractory multiple myeloma, with ongoing development in newly diagnosed patients as well. Key presentations include updated results from DREAMM-8, which provides a median follow-up of 35.8 months and examines both the depth of response and the durability of benefits in patients with relapsed or refractory multiple myeloma.

Also Read: WHO Issues First GLP-1 Guidelines to Combat Global Obesity

A post hoc analysis of DREAMM-7 will investigate patient characteristics and outcomes linked to extended responses, particularly in individuals achieving progression-free survival beyond three years. In addition, a combined subgroup analysis of DREAMM-7 and DREAMM-8 will evaluate progression-free survival and minimal residual disease negativity in patients with functional high-risk relapsed or refractory multiple myeloma treated with belantamab mafodotin versus standard-of-care therapies. Findings from DREAMM-9, focused on transplant-ineligible, newly diagnosed multiple myeloma patients, will explore whether higher initial dosing can optimize response, followed by adjusted dosing to minimize eye-related side effects.

GSK will also present new analyses of momelotinib, building on positive results from the MOMENTUM and SIMPLIFY trials, evaluating endpoints such as spleen size, anaemia, and overall survival. Additional data from MOMENTUM and SIMPLIFY-1 demonstrate momelotinib’s ability to improve haemoglobin levels and achieve dual benefits—transfusion independence and spleen volume reduction—while assessing how these outcomes impact survival in myelofibrosis patients, including those with prior JAK inhibitor treatment. Preliminary efficacy and safety results from the ODYSSEY trial, the first combination study of momelotinib with luspatercept, will also be shared.